Good Therapeutics

# Good Therapeutics: A Biopharmaceutical Pioneer in Conditionally Active Therapeutics

High-Level Overview

Good Therapeutics is a biopharmaceutical company that develops a novel class of self-regulating drugs designed to activate only at their intended targets in the body.[1] Founded in 2016 and based in Seattle, the company pioneered conditionally active protein therapeutics—drugs that reversibly switch from inactive to active forms only when they bind to specific molecular targets.[3] This approach addresses a critical challenge in drug development: maximizing therapeutic efficacy while minimizing systemic toxicity.

The company's initial focus centered on immuno-oncology, particularly developing IL-2-based therapies that activate only when bound to immune cells recognizing tumors.[3] Good Therapeutics' technology combines an antibody-binding domain that acts as a sensor with a therapeutic domain (such as a cytokine), enabling healthcare providers to build therapies that maximize patient benefit without sacrificing safety.[1] The company raised $22 million in Series A funding and an additional $8 million in Series B funding before its acquisition.[3]

Origin Story

Good Therapeutics was founded in 2016 by John Mulligan, Ph.D., a molecular biologist with a doctorate from Stanford University.[3][4] Mulligan brought substantial entrepreneurial experience to the venture, having previously founded Glycostasis (a company focused on insulin regulation) and co-founded Cambrian Genomics (which developed DNA laser-printing technology).[3] He also worked as a consultant for Microsoft on DNA data storage systems, demonstrating his deep expertise in molecular biology and biotechnology innovation.[3]

The company's founding was rooted in two core convictions: the belief that drugs could regulate their own activity and that selling individual programs—rather than platforms—represented a viable business model.[6] Early seed investments came from Mulligan himself and Codon Capital.[3] The company quickly attracted backing from prominent venture investors, including the Roche Venture Fund, RiverVest Venture Partners, Digitalis Ventures, and 3×5 Partners.[3]

Core Differentiators

Technology Platform

• Shape-shifting protein design: Good's therapeutics reversibly switch between inactive and active states based on target binding, enabling context-dependent activation.[3][6]
• Sensor-therapeutic architecture: The platform combines an antibody-binding domain (sensor) with a therapeutic component, allowing the drug to activate only when the sensor binds its intended target.[1][2]
• Broad applicability: The technology can target any molecule that an antibody can bind, including native proteins, modified proteins, and metabolites.[1]

Clinical Focus

• IL-2 cytokine regulation: The lead program targets PD-1-regulated IL-2, addressing the challenge of IL-2's potent anti-cancer activity coupled with significant systemic toxicity.[3][6]
• Preclinical pipeline: The company developed multiple programs including PD-L1-dependent interferon alpha and transforming growth factor beta blockers, all in preclinical stages.[7]

Team Strength

• In 2021, Good Therapeutics recruited Neela Patel as chief business officer (formerly executive director of corporate development at Seagen) and promoted Diane Hollenbaugh to chief scientific officer (formerly executive director of immuno-oncology discovery at AbbVie).[3] This leadership depth signaled the company's commitment to advancing its programs toward clinical development.

Role in the Broader Tech Landscape

Good Therapeutics emerged at a pivotal moment in immuno-oncology when the field was grappling with a fundamental trade-off: how to harness the power of immune-modulating molecules like IL-2 without causing severe systemic toxicity.[3] The company's conditionally active approach represented a paradigm shift—rather than accepting toxicity as an inevitable cost of efficacy, Good's technology engineered drugs to self-regulate based on their biological context.

This innovation aligned with broader industry trends toward precision medicine and targeted therapeutics, where the goal is to maximize therapeutic benefit while minimizing off-target effects. The timing was particularly favorable, as major pharmaceutical companies like Roche were actively seeking innovative approaches to strengthen their immuno-oncology portfolios.[6]

Good Therapeutics' acquisition by Roche in August 2022 for $250 million upfront plus potential milestone payments validated the commercial viability of conditionally active therapeutics and demonstrated that even early-stage (preclinical) programs with novel mechanisms could command significant valuations from Big Pharma.[4][6] The deal also highlighted the company's influence on the broader biotech ecosystem: rather than disappearing post-acquisition, Good's technology and team spawned Bonum Therapeutics, a spinout that secured $93 million in Series A funding to apply the same platform to other therapeutic targets.[2]

Quick Take & Future Outlook

Good Therapeutics' trajectory—from founding to $250 million acquisition to spinout—illustrates the power of solving a fundamental problem in drug development with an elegant technological solution. The company proved that conditionally active proteins could work, validating Mulligan's original thesis.[6]

The future of this technology extends well beyond oncology. Bonum Therapeutics is now exploring applications in autoimmunity, metabolic disorders, and pain management, suggesting that the conditionally active platform has broad potential across therapeutic areas.[2] As the field matures, we can expect to see clinical data emerging from Roche's PD-1-regulated IL-2 program, which will be the critical test of whether this elegant concept translates into meaningful patient benefit. If successful, conditionally active therapeutics could become a standard approach for any drug class where systemic toxicity limits efficacy—potentially reshaping how the industry thinks about drug design and safety.